H-1B Filings
85
Major sponsor. DOL labor condition applications on file.
Novartis Pharmaceuticals CORPORATION in NJ (Professional & Technical Services) shows all three federal tracks on this profile: 85 H-1B LCAs, an employer OSHA injury record, and 42 WARN notices.
Novartis Pharmaceuticals CORPORATION (NJ): · 85 H-1B LCAs at a $142,730 disclosed median · OSHA Grade A (DART 0.05) · 42 WARN notices
According to DOL OFLC H-1B disclosures, OSHA ITA injury logs, and state WARN Act notices, Novartis Pharmaceuticals CORPORATION in NJ carries 85 H-1B wage filings on record, a $142,730 median wage across 71 disclosed-wage positions (above the $124,488 national median), a strong A OSHA safety grade and 42 WARN layoff notices on file. Every figure is a federal filing, not an estimate; see methodology for coverage limits.
Layoff & federal record
Compared with the rest of PlainEmployers' federal employer corpus, H-1B filing volume ranks #552 of 51,370 sponsors in this corpus (about the 99th percentile), and disclosed median wage sits at the 64th percentile of 272,125 credible H-1B wage rows.
Figures above come from DOL H-1B LCAs, this employer's OSHA injury log, and state WARN notices, three independent disclosure systems.
A weighted composite of DOL H-1B sponsorship and pay, OSHA establishment injury records, and WARN Act layoff notices, not culture, benefits, or "is this a good place to work." Missing tracks drop out and their weight redistributes so sparse records are not silently deflated.
Weights (redistributed when a track is N/A): Sponsorship scale (H-1B volume) 15% · Disclosed pay (H-1B wage percentile) 25% · Workplace safety (OSHA DART percentile) 35% · Layoff stability (WARN percentile) 25%. Sources: DOL OFLC · OSHA ITA · state WARN filings.
DOL LCA release change
H-1B Filings
85
Major sponsor. DOL labor condition applications on file.
Median H-1B Salary
$142,730
Above national median. Across 71 disclosed positions
OSHA Safety Grade
Grade A · DART 0.05
Safer than industry average. vs 0.27 same 2-digit NAICS sector (OSHA ITA 2022–2023, hours-weighted)
WARN Workforce Impact
3,639 workers
Less stable than most peers. 42 WARN Act notices on file
Where Novartis Pharmaceuticals CORPORATION's H-1B wage sits nationally
Median disclosed wage vs. all US employers with H-1B filings
$142,730 Top 36% higher than 64% of 272,125 US employers
Each bar is a $20K-wide band; taller bars hold more US employers. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count, share, and where it sits relative to this entry.
Source DOL Office of Foreign Labor Certification, H-1B Disclosure Data · August 2026
Filing-count-weighted median across this employer's own disclosed H-1B positions (+0.5% year over year), not a company-wide raise, and not adjusted for role mix changes between years.
| Field | Value | Source |
|---|---|---|
| Employer Name | Novartis Pharmaceuticals CORPORATION | DOL OFLC / OSHA / WARN |
| Industry | Professional & Technical Services | NAICS / DOL |
| State | NJ | U.S. Federal Records |
| H-1B Filings | 85 | DOL OFLC LCA Disclosure |
| H-1B Median Salary | $142,730 | DOL OFLC LCA Disclosure |
| OSHA Safety Grade | A | OSHA ITA |
| OSHA DART Rate | 0.05 | OSHA ITA Establishment Records |
| WARN Layoff Notices | 42 notice(s), 3,639 workers | WARN Act notices, state workforce agency originals (archival backstop: LayoffData.com) |
Novartis Pharmaceuticals CORPORATION's values above reflect the most recent DOL Labor Condition Applications, OSHA Injury Tracking Application records, WARN Act notices on file for this employer in NJ (Professional & Technical Services). In this corpus, H-1B filing volume ranks #552 of 51,370 sponsors in this corpus (about the 99th percentile); disclosed median wage sits at the 64th percentile of 272,125 credible H-1B wage rows; OSHA DART rate is safer than roughly 63% of 214,554 employers with an establishment injury record.
| Job Title | Median |
|---|---|
| Executive Director, Forecasting | $241,592 |
| Director, AI Engineering | $223,642 |
| Director, Emerging Data Products - NS | $223,642 |
| Technology Product Director | $223,642 |
| Head of Strategy, US | $223,142 |
| Director, Resource Optimization Commercial | $223,142 |
| Product Strategy Lead, Stroke Prevention in A-Fib | $199,410 |
| ED, Portfolio & Early Pipeline Strategy | $199,410 |
| AD,Software Architect,Full Stack,RWD Sol | $187,741 |
| Associate Director, Web Platform Ops & Solutions Designs | $186,056 |
| Director, AI Use Case Lead | $185,723 |
| Sr. Global Program Safety Lead | $183,186 |
| Associate Director, Biostatistics | $175,781 |
| Associate Director, Product Adoption | $170,373 |
| Director, Integrated Analytics (Renal) | $170,373 |
| Associate Director, Business Performance | $169,541 |
| Director, Integrated Field Insights & Analytics | $169,541 |
| AD, Patient and Provider Analytics - CRM | $169,541 |
| Associate Director, Patient & Provider Analytics | $169,541 |
| AD, Integrated Field Execution Effectiveness - CE | $169,541 |
| Associate Director, PSC Operations Insights | $169,541 |
| Director, Forecasting-CV | $169,541 |
| Associate Director, Business Performance - CRM | $169,541 |
| Director, Integrated Field Targeting and NBA - CE | $169,541 |
| Associate Director, Monitoring and Standards | $169,541 |
| BPO Order Management & Finance, C&G | $169,541 |
| Associate Director, Integrated Field Targeting & NBA | $169,541 |
| Director, BD&L, Insights and Decision Science | $169,541 |
| Sr. Principal AQS Tech & Scientific Com | $161,803 |
| Director, Medical Science Liaison | $161,138 |
| Associate Director, NPS Product Management | $158,974 |
| Associate Director Patient Marketing Vijoice | $156,894 |
| Director, Product Strategy Counsel | $156,832 |
| Manager, HCP Education Delivery | $143,250 |
| Senior Principal Biostatistician | $142,771 |
| R&D/Tech Dev Quality Lead, Compliance | $142,730 |
| Clinical Trial Leader I | $141,398 |
| Study Leader | $141,398 |
| Global Regulatory Submission Manager | $141,190 |
| Associate Director, Commercial Analytics | $141,170 |
| Associate Director, Product Management | $141,170 |
| Associate Director, Resource Optimization | $141,170 |
| Associate Director, Emerging Data Products | $139,506 |
| AD, Integrated Field Deployment & GTM Analytics | $139,506 |
| Director - Decision Science, Immunology Product Lead | $138,466 |
| Principal Biostatistician | $133,904 |
| Operational Health Project Manager | $129,709 |
| Senior Principal Biostatistician | $127,858 |
| Associate Director, Business Applications Product Owner | $126,818 |
| Senior Manager, Functional Reporting | $126,818 |
WARN history dominates: 42 notices put this employer among the 100% with the heaviest layoff filings in the corpus.
Novartis Pharmaceuticals CORPORATION in NJ (Professional & Technical Services) filed 85 H-1B labor condition applications, of which 71 disclose a usable wage figure at a $142,730 disclosed median — a top-tercile sponsorship footprint in this corpus.
FY2025 added 20 filings versus FY2024 (222.2%), a sponsorship expansion visible in the raw LCA counts.
DART 0.1 tracks close to the 0.3 sector average (Grade A).
Novartis Pharmaceuticals CORPORATION is one of the rarer profiles carrying both sponsorship volume (85 H-1B LCAs) and WARN history (42 notices) in the same public record (Professional & Technical Services) in NJ. Weigh those signals separately.
A $142,730 disclosed median lands near the middle of the wage distribution (64th percentile vs $124,488 nationally).
Novartis Pharmaceuticals CORPORATION's DART rate (days away/restricted/transferred per 100 FTE) vs the hours-weighted 2-digit NAICS sector average from OSHA ITA 2022–2023 (Professional & Technical Services).
Total reported injuries on file: 11.
Where Novartis Pharmaceuticals CORPORATION sits
Across the 199 Professional & Technical Services sponsors in this corpus with both an H-1B filing count and a credible disclosed-wage median, Novartis Pharmaceuticals CORPORATION files more petitions than 7% of them and discloses a higher median wage than 67%, the selective, above-median pay quadrant. Filing volume is hiring scale, not pay; the axes are independent DOL OFLC disclosures (85 filings · $142,730 median here).
Each muted dot is one professional & technical services peer from a filings-stratified sample of 42; the brand marker is Novartis Pharmaceuticals CORPORATION. Source: DOL Office of Foreign Labor Certification H-1B LCA disclosures (credible wages recomputed from per-position filings, excluding parse errors above $500k).
Novartis Pharmaceuticals CORPORATION's nearest H-1B-filing peers in Professional & Technical Services (home state NJ). Each card links to that employer's federal-records profile.
Two federal-records peer sets for Novartis Pharmaceuticals CORPORATION, both outside NJ so the neighborhoods are not the same-industry VsCard above.
Nearest injury-rate peers outside NJ (DART 0.05 here).
Peers are nearest-neighbor matches on disclosed filing counts and OSHA ITA DART rates; employers with fewer than 100 H-1B filings or fewer than 10 reported injuries are excluded from the comparison corpus.
| Notice Date | Workers |
|---|---|
| 2023-08-01 | 103 |
| 2022-11-01 | 221 |
| 2021-06-01 | 186 |
| 2014-12-01 | 200 |
| 2014-04-01 | 47 |
| 2014-04-01 | 38 |
| 2014-04-01 | 38 |
| 2014-04-01 | 32 |
| 2014-04-01 | 15 |
| 2014-04-01 | 10 |
| 2014-04-01 | 9 |
| 2014-04-01 | 3 |
| 2014-04-01 | 2 |
| 2014-04-01 | 2 |
| 2014-04-01 | 2 |
| 2014-04-01 | 1 |
| 2014-04-01 | 1 |
| 2014-04-01 | 1 |
| 2014-04-01 | 1 |
| 2014-03-01 | 2 |
| 2014-02-01 | 2 |
| 2014-02-01 | 561 |
| 2014-02-01 | 23 |
| 2014-02-01 | 8 |
| 2014-02-01 | 8 |
| 2014-02-01 | 4 |
| 2014-02-01 | 4 |
| 2014-02-01 | 2 |
| 2014-02-01 | 4 |
| 2012-04-01 | 1,380 |
| 2012-04-01 | 93 |
| 2012-04-01 | 45 |
| 2012-04-01 | 35 |
| 2012-04-01 | 32 |
| 2012-04-01 | 27 |
| 2012-04-01 | 5 |
| 2012-03-01 | 5 |
| 2012-02-01 | 14 |
| 2012-02-01 | 247 |
| 2012-01-01 | 43 |
| 2011-11-01 | 145 |
| 2011-11-01 | 38 |
What to check before working with Novartis Pharmaceuticals CORPORATION
Novartis Pharmaceuticals CORPORATION needs a three-way read: H-1B pay (85 LCAs), safety (grade A), and WARN history (42 notices); none of those alone is the rating.
Novartis Pharmaceuticals CORPORATION's figures are legally filed public records (DOL, OSHA, state WARN), not reviews or vendor estimates; a missing row is not proof the underlying activity never happened.
Disclaimer: This information is provided for informational purposes only and does not constitute professional advice. Data is sourced from OSHA and the DOL Wage and Hour Division. Consult a qualified professional before making decisions based on this data.
Among 272,125 credible H-1B wage rows in this corpus, Novartis Pharmaceuticals CORPORATION's disclosed median of $142,730 sits at the 64th percentile (above the $124,488 national median). The chart above uses a COUNT-exact percentile (rows below this wage ÷ total), not an interpolated estimate.
Novartis Pharmaceuticals CORPORATION has 85 H-1B filings on record, ranking #552 of 51,370 sponsors in this corpus (about the 99th percentile by volume). Filing volume is a sponsorship signal, not a headcount or hiring-quality score.
Novartis Pharmaceuticals CORPORATION carries Grade A from its establishment injury record (11 injuries on file; DART 0.05). That DART rate is safer than roughly 63% of 214,554 employers with an injury record in this corpus. Grades compare DART against industry averages, see the Interpreting Safety Grades guide.
Yes - 42 WARN Act notices affecting about 3,639 workers appear in the state-agency corpus for this employer. WARN covers mass layoffs and plant closings that meet statutory thresholds; absence of notices is not a guarantee of stability.
Related guides: How OSHA safety grades are calculated · Using H-1B wage filings in salary negotiation
Read our methodology - how this data is sourced, computed, and verified.
This profile is rendered directly from DOL H-1B disclosure filings, OSHA Injury Tracking Application records and state WARN Act layoff notices, no number is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error. Data current as of August 2026.